BCAAs are key ingredients of WPs with biomodulatory effects. We recently reported that a highly-concentrated low-dose (10g, 40 Cal) WP pre-meal drink (125 mL) , generated with novel micelle-technology (WP microgel [WPM]) , ingested 15 min ahead of a pizza-meal (622 Cal) , vs placebo (PBO) , reduced the 2h incremental area under the glucose curve (iAUC) by 22%, increased 2h GLP-1 iAUC by 61% and, delayed 1h gastric emptying by 17%, in 26 people with T2D. Here, we analyzed 2h free plasma BCAA trajectories in 25 persons (mean age 62 yrs, HbA1c 7,5%, BMI 29 kg/m2) that completed this single dose study. The pre-meal WPM drink significantly altered the BCAA trajectory vs. PBO (Figure) . For leucine, ΔiAUCWPM vs PBO increased by 267%, with a shorter time to maximum (median ΔTmax [min, max]: -60 [-120,0] min, p<0.0001) , and peak concentration (mean ΔCmax [SD]: 123 [49] umol/L, p<0.0001) . A similar pattern was seen for isoleucine (ΔiAUC +240%, ΔTmax: -60 [-120,0], p<0.0001, ΔCmax: 68 [31], p<0.0001) and valine (ΔiAUC +194%, ΔTmax: -60 [-120, 30], p < 0.0001, ΔCmax: 63 [38], p<0.0001) . We conclude that 10g WPM as a pre-meal drink, induced a rapid plasma increase, and high bioavailibilty, of BCAAs in people with T2D. The rapid BCAA availability might be a likely factor for the metabolic modulatory effects observed with WPM.


I.Neeland: Advisory Panel; Boehringer Ingelheim International GmbH, Merck & Co., Inc., Consultant; Nestlé Health Science. B.Ahrén: Speaker's Bureau; Nestlé, Novo Nordisk, Stock/Shareholder; AstraZeneca, Novo Nordisk A/S. J.V.Corthésy: Employee; Nestlé. Y.Grzywinski: None. Z.Magos: Consultant; Nestlé Health Science. M.Von eynatten: Employee; Nestlé Health Science. O.Johansen: Employee; Boehringer Ingelheim International GmbH, Nestlé Health Science.


Nestlé Health Science

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.